JP / EN
Adopted for San Diego "CONNECT" Acceleration Program
Yoji Jokura has been appointed as Board Chairman and Chiaki Waki has been appointed as President&CEO.
CTBE was accepted by Johnson & Johnson Innovation (Boston, U.S.A.) as the first startup company in Japan. It was also interviewed and posted by Nikkei Shimbun.
CTBE was introduced by "Venture Tanbou" on "Nikkei Biotechnology & Business".
CTBE was elected to "J-Startup", the program for supporting the global startup companies sponsored by Japanese governmental organizations (METI, JETRO and NEDO).
CTBE raised fund from SUCCESS program of Japan Science and Technology Agency (JST) . The company will accelerate development of the artificial ligament for ACL reconstruction and business development for the US market.
CTBE moved to new office with R/D laboratory and manufacturing facility.
CTBE presented at Startup Pitch@CIC sponsored by CIC Tokyo and Tokyo University Biodesign and won a prize.
CTBE obtained the manufacturing and marketing authorization of the highly controlled medical devices.
AMED adopted CTBE to the Grant, "the 5th CiCLE: Cyclic Innovation for Clinical Empowerment 2020"
CoreTissue BioEngineering and Teijin Limited agree on alliance to mass produce artificial ligament
The annual report of the AMED grant program was published
CTBE conducted FDA Pre-Submission with the U.S, Food and Drug Administration (FDA) successfully. For Reference
The CEO went onto the online platform of the Joint Pitch - Deep Tech for Good: Medical Innovations sponsored by SGInnovate (Singapore) and Japan Science and Technology Agency (JST)
The 2020 renewal of the AMED grant program was approved
The CEO went onto the platform of the 34th NEDO Pitch "Academic Venture x Health-tech"
Received grant from the Ogasawara Foundation for the Promotion of Science & Engineering
Funded as the first investment by Waseda University Official Fund